Omnicare Clinical Research Re-Brands as Theorem Clinical Research
Omnicare Clinical Research announces the re-branding of the company under the name Theorem Clinical Research. The brand launch marks the final step in the CRO's separation from its former parent company in a deal that was finalized this spring.
Nautic Partners, LLC, a private equity firm based in Providence, R.I., acquired the CRO in a transaction publicized in April. The signing of the deal not only made official the separation of Omnicare Clinical Research from former parent company, Omnicare, Inc., it accomplished the company‟s most visible step in achieving the long-identified goal: to stand on its own and deliver results the way that clients need.
Now, under the new name, Theorem Clinical Research will bring its more than two decades of experience and industry leadership to manage complex trials. With approximately 1,000 dedicated professionals and locations around the globe, Theorem Clinical Research will continue to provide full-service clinical trial management, with a continued focus on its core CRO (Early Phase, Phase II/III, Late Phase) and its specialized business units:
· Pharmaceutics
· Medical Device
· Technical Services (Biometrics & Clinical Data Management)
“The re-branding of the company is not something that happened overnight,” says Dr. James Pusey, President & CEO, Theorem Clinical Research. “This is 25 years in the making. We are now able to be more agile and efficient since we are now in the driver‟s seat of our own company. We strive to be able to work the way our clients do; from our specialized business units to our 32 locations, Theorem Clinical Research (aims) to give clients exactly what they need.”
Theorem will be at the 47th Annual Drug Information Association (DIA) Meeting, June 19-23 in Chicago to kick-off the new brand. Visit them at Booth 529.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
